Skip to main content
. 2023 Apr 1;9:110. doi: 10.1038/s41420-023-01407-z

Fig. 4. Regulatory mechanisms of chemotherapeutic agents targeting ferroptosis in lung cancer.

Fig. 4

CDDP Cisplatin, SOR Sorafenib, AF Auranofin, LEV Levobupivacaine, AFC Ammonium Ferric Citrate, PdPT Palladium pyrithione complex, FLD Falnidamol, APAP Acetaminophen, SAHA Vorinostat, IKE Imidazole ketone erastin, ZVI-NP Zero-valent-iron nanoparticle, FTG/L&SMD Multifunctional “ball-rod” Janus nanoparticles, FAF2 fatty acid synthase-associated factor 2, HMOX1 Heme oxygenase 1, GOD glucose oxidase, OH• reactive hydroxyl radical, TrxR thioredoxin reductase 1, DUSP26 Dual-specificity phosphatase 26, GSK3 phospho-glycogen synthase kinase 3, β-TrCP beta-Transducin repeats-containing protein, Nrf2 nuclear factor erythroid 2-related factor 2, p53 tumor suppressor protein, GPX4 glutathione peroxidase 4, System Xc− cystine/glutamate antiporter system, Cys2 cystine, Glu glutamate, Cys cysteine, Gly glycine, GCL glutamate-cysteine ligase, SLC3A2 solute carrier family 3, member 2, SLC7A11 solute carrier family 7 (L-type amino acid transporter), member 11, GSS glutathione synthetase, GSH glutathione, GSSG oxidized glutathione, GSR glutathione reductase, ROS reactive oxygen species.